

September 23, 2020

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announced today that on September 15, 2020 it established Sumitomo Pharmaceuticals Taiwan Co., Ltd. (hereinafter, "SPTW") as a wholly owned subsidiary of Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. (hereinafter, "SPAP"), a wholly owned subsidiary of Sumitomo Dainippon Pharma.

In the future, SPTW will start selling our pharmaceutical products in Taiwan. From its subsidiaries in China, Singapore, and Thailand, Sumitomo Dainippon Pharma is dedicating its focus to the fast-growing Asian market. Now that we have a base for autonomous operations in Taiwan, we intend to further expand our business in the Asian market.

<Reference: About Sumitomo Pharmaceuticals Taiwan Co., Ltd.>

Company Name	Sumitomo Pharmaceuticals Taiwan Co., Ltd.
Establishment	September 15, 2020
Representative	Toyohiro Yoneda
Share capital	35.0 million New Taiwan dollar (approx. 123.0 million yen*)
Number of employees	16
Functions	Sale of ethical drugs and provision and collection of information on products to/from medical professionals in Taiwan
Ownership	SPAP
Location	Taipei

* 1 New Taiwan dollar = 3.5 yen

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)